Advanced search
Start date

Development of multifunctional prodrugs for combination therapy against hepatocellular carcinoma and HCV

Grant number: 15/23244-8
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): April 01, 2016
Effective date (End): August 31, 2020
Field of knowledge:Biological Sciences - Biochemistry - Chemistry of Macromolecules
Principal Investigator:Eduardo Maffud Cilli
Grantee:Paulo Ricardo da Silva Sanches
Home Institution: Instituto de Química (IQ). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Associated research grant:13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery, AP.CEPID
Associated scholarship(s):19/08342-4 - Development of bioconjugates containing peptides for combined therapy aimed the treatment of Zika and Dengue virus infection, BE.EP.DR


Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of death worldwide. Alcohol and viral infections are the leading causes of this disease. About 90% of HCC cases are attributed to infection by Hepatitis B and C. Unlike HBV, there is still no vaccine capable of preventing infection by HCV. Most of therapeutic agents (anti-tumor and antiviral) in use is generally not specific for affected cells and the virus, causing side effects. The drug combination and development of prodrugs have been shown to be effective in the treatment of infections and tumors, opening up new opportunities for the development of more potent and less aggressive compounds to the healthy cells. The aim of this work is to develop prodrugs that are able to internalize and deliver drugs with different mechanisms of action, and targets (antitumor and antiviral), in order to develop a combined therapy against HCV and hepatocellular carcinoma. We intend to combine the antitumor curcumin and the indole derivative 3- (3,4,5-trimethoxyphenyl) -1,2,3,4-tetrahydrocyclopentaindole-2-carboxylic acid and the antiviral ribavirin in a single structure (prodrugs ) containing the galactose binding specificity to promote greater tumor cells. Peptide sequences containing the cleavage site of the lysosomal enzyme cathepsin B and the viral NS3 protease / NS4A are also used to verify the release of the drug. The synthesis of these compounds will be performed by SPPS with purification and characterization by HPLC and LC-MS, respectively. Serum stability assays, release of the drug, cell viability by MTT, flow cytometry, luciferase assays, Western blotting and quantification of viral load by real-time PCR will provide results that bear relevance of these new molecules to intervene in cell proliferation of liver cancer and HCV infection

Matéria(s) publicada(s) na Agência FAPESP sobre a bolsa:
Scientists synthesize molecule capable of eliminating hepatitis C virus 

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
BATISTA, MARIANA NOGUEIRA; DA SILVA SANCHES, PAULO RICARDO; CARNEIRO, BRUNO MOREIRA; SILVA BRAGA, ANA CLAUDIA; FERNANDES CAMPOS, GUILHERME RODRIGUES; CHILLI, EDUARDO MAFFUD; RAHAL, PAULA. GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals. SCIENTIFIC REPORTS, v. 8, SEP 25 2018. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: